The FDA's Protocol Deviation draft guidance is very much in line with the TransCelerate recommendations. My recommendation for the sponsors is to read through the document and provide comments to ...

Serious breach: Any deviation of the approved protocol version or the clinical trial regulation that is likely to affect the safety, rights of trial participants and/or data reliability and robustness ...